drugset / Trial / NCT04526509
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.
Timeline
- Start
- 2020-12-21
- Primary completion
- 2023-06-08
- Completion
- 2023-06-08
Outcome
Outcome not reported
Stopped: “The study was terminated due to a change in GSK's R\&D priorities.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK3845097 | Cell therapy | — | Intravenous |
| Subject | GSK3901961 | Cell therapy | — | Intravenous |
| Subject | GSK4427296 | Unknown | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |